Keryx Biopharma (KERX) Posts Narrower than Expected Q2 Loss of 2c/Share

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q2 EPS of ($0.02), $0.07 better than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Bank of America to acquire up to 49.9% stake in Jio Credit for ~$1.9B
• The Honest Co. (HNST) PT Raised to $5.70 at Morgan Stanley, 'Diaper Pressure Continues'